Evidence map›Paper›PMID 41853742›Full record

ArticleKidney international reports2026

Update on Alport Syndrome: The Report of the 2024 International Workshop on Alport Syndrome.

Thomas M Oates, Moumita Barua, Susie Gear, A Neil Turner, Rachel Lennon, Hirofumi Kai, Daniel P Gale, Marina Aksenova, Judith Savige, Oliver Gross and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thomas M OatesRoyal London Hospital, Barts Health NHS Trust, London, UK.
Moumita BaruaToronto General Hospital, Toronto General Research Institute, University of Toronto, Toronto, Ontario, Canada.
Susie GearAlport UK, Tetbury, UK.
A Neil TurnerRenal Medicine, Royal Infirmary, University of Edinburgh, Edinburgh, UK.
Rachel LennonWellcome Centre for Cell-Matrix Research, University of Manchester, Manchester, UK.
Hirofumi KaiDepartment of Molecular Medicine, Kumamoto University, Kumamoto, Japan.
Daniel P GaleDepartment of Renal Medicine, University College London, London, UK.
Marina AksenovaY. Veltischev Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University, Taldomskaya Street, Moscow, Russia.
Judith SavigeDepartment of Medicine (Melbourne Health and Northern Health), The University of Melbourne, Parkville, Victoria, Australia.
Oliver GrossClinic for Nephrology and Rheumatology, University Medicine Goettingen, Goettingen, Germany.
Laura MassellaDivision of Nephrology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Jeffrey H MinerDivision of Nephrology, Department of Medicine and Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Constantinos DeltasSchool of Medicine, University of Cyprus, Nicosia 2109, Cyprus.

Funding

Innovative Approaches to Treating Alport SyndromeR01DK128660 · NIDDK · WASHINGTON UNIVERSITY · PI MINER, JEFFREY H · 2021 to 2025
$2.2M
NIDDK NIH HHS R01 DK128660
6 · The paper itself

Abstract

The 2024 International Workshop on Alport syndrome brought together people living with Alport Syndrome, clinicians, laboratory scientists, and representatives of pharmaceutical companies to present recent data and discuss issues to advance understanding of this inherited condition. The workshop focused on diagnosis and management of Alport syndrome, with particular attention on genetic variant curation, and treatment strategies across the diverse spectrum of Alport syndrome phenotypes, from hematuria to early kidney failure, with or without hearing loss and eye abnormalities. Advances in genetic testing, especially for non-European populations, were discussed alongside challenges in variant interpretation and misclassification. Novel treatment approaches, including gene therapy, and ongoing trials of medications such as sodium-glucose cotransporter 2 inhibitors and endothelin receptor antagonists, offer hope for prolonging kidney function. Collaboration between high- and low-to-middle-income countries was highlighted, addressing disparities in diagnostic capabilities. In addition, the role of patient advocacy and the need for education in nephrology were emphasized. With ongoing research, Alport syndrome is moving closer to being not only actionable but highly treatable through the prevention of kidney failure.

Identifiers

PMID41853742
PMCPMC12995486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.